A Multicenter, Open, Extension Trial to Evaluate Safety and Efficacy of Recombinant Human Coagulation Factor VIII (SCT800) During Long Term Treatment in Previously Treated Patients With Severe Haemophilia A
Latest Information Update: 10 Aug 2022
At a glance
- Drugs Omfiloctocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Sponsors Sinocelltech
Most Recent Events
- 17 Jun 2022 Results for the extension study (n=69; As of 24 Feb 2022) assessing long term safety and efficacy of Sct800 in previously treated patients (greater than equal to 12 years) with severe hemophilia A, presented at the 27th Congress of the European Haematology Association.
- 16 May 2019 New trial record